XenoPort shares skid after MS drug proves to be a lemon in PhIII – FierceBiotech

by admin on May 20, 2013

XenoPort shares skid after MS drug proves to be a lemon in PhIII
FierceBiotech
The troubled biopharma company, which has been struggling to spur sales for the approved drug Horizant for restless leg syndrome, immediately opted to bury the program. Santa Clara, CA-based XenoPort didn't spell out the data, but the drug–arbaclofen

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: